GERN:NGS-Geron Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 3.58

Change

+0.08 (+2.29)%

Market Cap

USD 0.34B

Volume

6.97M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Geron Corp is a biopharmaceutical company that supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 96.94B
MRNA Moderna Inc

N/A

USD 38.83B
ARGX argenx NV ADR

N/A

USD 23.13B
BNTX BioNTech SE

N/A

USD 22.34B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 19.27B
GMAB Genmab AS

N/A

USD 18.26B
RPRX Royalty Pharma Plc

N/A

USD 16.73B
BGNE BeiGene Ltd

N/A

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.35B

ETFs Containing GERN

WDNA 2.70 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.24 % 0.00 %

N/A

USD 6.95M
WDNA:LSE WisdomTree BioRevolution .. 2.24 % 0.00 %

N/A

USD 2.65M
WRNA:XETRA WisdomTree BioRevolution .. 2.21 % 0.00 %

N/A

USD 2.77M
QQQS Invesco NASDAQ Future Gen.. 0.83 % 0.00 %

N/A

USD 8.10M
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

N/A

USD 0.02B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD 0.26B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 69.67% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.67% 88% B+ 94% A
Trailing 12 Months  
Capital Gain 47.33% 81% B- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.33% 81% B- 86% B+
Trailing 5 Years  
Capital Gain 87.43% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.43% 85% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 26.65% 77% C+ 84% B
Dividend Return 26.65% 77% C+ 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.99% 49% F 29% F
Risk Adjusted Return 47.61% 92% A 79% B-
Market Capitalization 0.34B 89% A- 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 7.86 18% 14%
Price / Cash Flow Ratio -11.65 84% 83%
Price/Free Cash Flow Ratio -9.74 87% 84%
Management Effectiveness  
Return on Equity -112.29% 36% 18%
Return on Invested Capital -84.13% 35% 14%
Return on Assets -41.47% 34% 12%
Debt to Equity Ratio 14.14% 52% 66%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector